1 - 7 of 7

Paul Gadue, PhD

Paul Gadue

Dr. Gadue studies cell fate decisions, focusing on endoderm and mesoderm specification using human embryonic stem (ES) cells and induced pluripotent stem (iPS).


Kaila Gammon

Kaila Gammon

Establishes a set of definitions, policies, and procedures to guide the involvement of individuals such as long-term collaborators, high school and college-level students, graduate students, and others who are not regular CHOP employees in the Research Institute’s programs.


Lindsey A. George, MD

Lindsey A. George

Dr. George's basic and clinical research interests are in the development of novel therapeutics for hemophilia. Her basic science laboratory studies the molecular basis of coagulation, and she is the principal investigator of ongoing hemophilia A and B gene therapy trials.


Jill P. Ginsberg, MD

Jill P. Ginsberg

Dr. Ginsberg serves as director of the Cancer Survivorship Program at Children’s Hospital of Philadelphia and has a robust research program on survivorship and fertility preservation for cancer patients.


Pedro Gonzalez-Alegre, MD, PhD

Dr. Gonzalez-Alegre’s long-range research goal is to advance the application of precision medicine in the neurology clinic. His research focus revolves around genetic disorders that affect the brain, spanning from the diagnosis of novel genetic disease in the clinic to the identification of novel molecular targets using disease models and the design of early-phase human clinical trials.

Dr. Gonzalez-Alegre's long-range research goal is to advance the application of precision medicine in the neurology clinic. His research focus revolves around genetic disorders that affect the brain, spanning from the diagnosis of novel genetic disease in the clinic to the identification of novel molecular targets using disease models and the design of early-phase human clinical trials.


Stephan A. Grupp, MD, PhD

Stephan A. Grupp

Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.